LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 4/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Eli Lilly and Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$829.84 |
52 Week High | US$972.53 |
52 Week Low | US$561.65 |
Beta | 0.40 |
11 Month Change | 2.94% |
3 Month Change | -9.08% |
1 Year Change | 40.83% |
33 Year Change | 239.65% |
5 Year Change | 587.07% |
Change since IPO | 29,446.46% |
Recent News & Updates
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Dec 04Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly
Nov 29Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Nov 28Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21Recent updates
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Dec 04Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly
Nov 29Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Nov 28Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next
Nov 01Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
Oct 30Eli Lilly Buy On Weakness Signal (Technical Analysis)
Oct 20Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Sep 30Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Sep 20Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Sep 18Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)
Aug 12Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic
Aug 04Shareholder Returns
LLY | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 5.3% | 0.8% | 0.4% |
1Y | 40.8% | 12.1% | 32.3% |
Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned 12.1% over the past year.
Return vs Market: LLY exceeded the US Market which returned 32.3% over the past year.
Price Volatility
LLY volatility | |
---|---|
LLY Average Weekly Movement | 4.3% |
Pharmaceuticals Industry Average Movement | 10.1% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
LLY fundamental statistics | |
---|---|
Market cap | US$732.35b |
Earnings (TTM) | US$8.37b |
Revenue (TTM) | US$40.86b |
89.3x
P/E Ratio18.3x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LLY income statement (TTM) | |
---|---|
Revenue | US$40.86b |
Cost of Revenue | US$7.80b |
Gross Profit | US$33.06b |
Other Expenses | US$24.69b |
Earnings | US$8.37b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 9.30 |
Gross Margin | 80.91% |
Net Profit Margin | 20.48% |
Debt/Equity Ratio | 218.1% |
How did LLY perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield54%
Payout RatioDoes LLY pay a reliable dividends?
See LLY dividend history and benchmarksEli Lilly dividend dates | |
---|---|
Ex Dividend Date | Nov 15 2024 |
Dividend Pay Date | Dec 10 2024 |
Days until Ex dividend | 20 days |
Days until Dividend pay date | 5 days |
Does LLY pay a reliable dividends?
See LLY dividend history and benchmarks